



# LAHIVE & COCKFIELD, LLP

JOHN A. LAHIVE, JR. (1928)  
W. HUGO LIEPMANN  
JAMES E. COCKFIELD  
THOMAS V. SMURZYNSKI  
RALPH A. LOREN  
THOMAS J. ENGELLENER  
GIULIO A. DeCONTI, JR.  
ANN LAMPORT HAMMITTE  
PAUL LOUIS MYERS, Ph.D.  
ELIZABETH A. HANLEY  
MICHAEL I. FALKOFF  
JOHN V. BIANCO  
AMY BAKER MANDRAGOURAS  
ANTHONY A. LAURENTANO  
JANE E. REMILLARD  
MARK A. KURISKO  
JEAN M. SILVERI  
PETER J. RAINVILLE  
CHARLES ERIC SCHULMAN  
FAUSTINO A. LICHAUICO

COUNSELLORS AT LAW  
28 STATE STREET  
BOSTON, MASSACHUSETTS 02109

TELEPHONE (617) 227-7400  
FAX (617) 742-4214  
lc@lahcoc.com

January 6, 1998

SCOTT D. ROTHENBERGER, Ph.D.  
DAVID A. LANE, JR.  
THOMAS P. GROOT

OF COUNSEL  
JEREMIAH LYNCH  
LAWRENCE E. MONKS  
WILLIAM A. SCOFIELD, JR.

TECHNICAL SPECIALISTS  
CATHERINE J. KARA, Ph.D.  
MARK D. RUSSETT  
IVANA MARAVIC-MAGOVCEVIC, Ph.D.  
MEGAN E. WILLIAMS, Ph.D.  
SONIA K. GUTERMAN, Ph.D.  
DIANA M. COLLAZO, Ph.D.  
JASBIR K. SAGOO, Ph.D.  
DEBRA J. MILASINCIC, Ph.D.  
MARIA C. LACCOTRIPE, Ph.D.  
LAURANNE S. BUTLER

Assistant Commissioner for Patents  
Washington, D.C. 20231

Re: U. S. Patent Application Serial No. 08/737,904  
Title: *T CELL EPITOPES OF RYEGRASS POLLEN ALLERGEN*  
Applicant(s): Irwin J. Griffith, et al.  
Filed: November 20, 1996  
Examiner: R. Schwadron; Group Art Unit: 1816  
Attorney Docket No. IMI-040CP3 (075.1 U.S.)

Dear Sir:

I enclose herewith for filing in the above-identified application the following:

1. Preliminary Amendment;
2. Response to "Notice to Comply with Requirements for Patent Application Containing Nucleotide and/or Amino Acid Sequence Disclosures";
3. A copy of "Notice to Comply with Requirements for Patent Application Containing Nucleotide and/or Amino Acid Sequence Disclosures";
4. Substitute pages 47-74 containing the Sequence Listing;
5. Diskette containing the Sequence Listing;
6. Transmittal letter for Diskette of Sequence Listing;
7. Request for Three-Month Extension of Time;
8. A check in the amount of \$475.00 (extension fee);
9. Notification of Change of Address; and
10. Receipt postcard.

U.S. Serial No. 08/737,904

Art Unit 1816

Please charge any necessary fees to our Deposit Account No. 12-0080.  
The undersigned requests any extensions of time necessary to respond. A  
duplicate of this sheet is enclosed.

I hereby certify that this correspondence is deposited with the  
United States Postal Service as first class mail in an envelope  
addressed to: Assistant Commissioner for Patents, Washington,  
DC 20231 on:

Date

Amy E. Mandragouras, Reg. No. 36,207

Respectfully submitted,

LAHIVE & COCKFIELD, LLP

Amy E. Mandragouras  
Reg. No. 36,207

JAN 14 1998



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Irwin J. Griffith et al.

Serial No.: 08/737,904

Filed: November 20, 1996

For: T CELL EPITOPES OF RYEGRASS POLLEN  
ALLERGEN

Attorney Docket No.: IMI-040CP3 (075.1 US)

Group Art Unit: 1816

Examiner: R. Schwadron

Assistant Commissioner for Patents  
Washington, D.C. 20231

Certificate of First Class Mailing (37 CFR 1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on the date set forth below.

January 6, 1998  
Date of Signature and of Mail Deposit

By: 

Amy E. Mandragouras  
Reg. No. 36,207  
Attorney for Applicant

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT  
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO  
ACID SEQUENCE DISCLOSURES**

Dear Sir:

Responsive, in part, to the "Notice to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures" and the Examiner's Communication, dated September 23, 1997 (a copy of both of which is attached herewith), Applicants have amended the Sequence Listing submitted on November 20, 1996 to include the two sequences shown in Figure 2, i.e., LIX-1 and LIX-2 wherein X is a hydroxyproline, which were objected to in the Examiner's Communication, and to correct the designation of the hydroxyproline residues in SEQ ID

NO: 54 of the Sequence Listing. In particular, Applicants have added the sequences LIX-1 and LIX-2 as SEQ ID NOs: 59 and 60, respectively, to the corrected Sequence Listing submitted herewith. The hydroxyproline residues are referred to in these sequences as Xaa with the additional inclusion in part (d) of the Feature section of the sequence identifier that Xaa is hydroxyproline. In addition, for consistency, Applicants have corrected the designation of the hydroxyproline residues in SEQ ID NO: 54 from Hyp to Xaa, with the additional inclusion in part (d) of the Feature section of the sequence identifier that Xaa is hydroxyproline.

A paper copy of the corrected Sequence Listing and a computer readable form of the sequence listing (diskette), which is identical in substance to the paper copy of the Sequence Listing in accordance with 37 C.F.R. §1.821(c) and (e), are also submitted herewith.

No new matter has been added to the application. Accordingly it is respectfully requested that the above amendments be entered.

Respectfully submitted,




Amy E. Mandragouras  
Registration No. 36,207  
Attorney for Applicants

LAHIVE & COCKFIELD, LLP  
28 State Street  
Boston, MA 02109

Dated: January 6, 1998

ENTERED



UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office  
COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
087737,904	11/20/96	GRIFFITH	I IMI040CP3

LAHIVE & COCKFIELD  
60 STATE STREET  
BOSTON, MA 02109

18M1/0923

EXAMINER	
SCHWADRON, R	
ART UNIT	PAPER NUMBER
1816	

DATE MAILED:

09/23/97

Please find below a communication from the EXAMINER in charge of this application

Commissioner of Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2).

However, no sequence listing has been submitted for the sequences of Figure 2 wherein x is hydroxyproline (eg. the sequence LIX-1 or LIX-2 wherein x represents hydroxyproline, etc).


Thus, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence and/Or Amino Acid Sequence Disclosures.


Any inquiry concerning this communication should be directed to Examiner Ron Schwadron, Art Unit 1816, whose telephone number is (703) 308-4680.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Ron Schwadron, Ph.D.  
September 19, 1997

  
RONALD B. SCHWADRON  
PRIMARY EXAMINER  
GROUP 1800

RECEIVED LAHIVE & COCKFIELD SEP 29 1997 BY 
---

Application No.: 08/737904

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING  
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: see enclosed note

**Applicant Must Provide:**

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Irwin J. Griffith et al.

Serial No.: 08/737,904

Filed: November 20, 1996

For: T CELL EPITOPES OF RYEGRASS POLLEN  
ALLERGEN

Attorney Docket No.: IMI-040CP3 (071.1US)

BOX SEQUENCE

Assistant Commissioner of Patents and Trademarks  
Washington, D.C. 20231

Group Art Unit: 1816


Examiner: R. Schwadron

Certificate of First Class Mailing (37 CFR 1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: BOX SEQUENCE Assistant Commissioner for Patents, Washington, D.C. 20231 on the date set forth below.

January 6, 1998  
Date of Signature and of Mail Deposit

By:

  
Amy E. Mandragouras  
Reg. No. 36,207  
Attorney for Applicant


**TRANSMITTAL LETTER FOR DISKETTE OF SEQUENCE LISTING**

Dear Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures, and the Examiner's Communication dated September 23, 1997, we enclose a diskette which contains a computer readable form of the Sequence Listing for the above-identified application.

Substitute pages 47 - 74 are submitted herewith. The material on the enclosed diskette is identical in substance to the enclosed sequence listing. The computer readable form of the Sequence Listing contained on the enclosed diskette is understood to comply with the requirements of §§ 1.821-1.825. No new matter has been added.

Respectfully submitted,

  
Amy E. Mandragouras, Esq.  
Registration No. 36,207  
Attorney for Applicants

Dated: January 6, 1998



Customer No.: 000959

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Irwin J. Griffith et al.

Group Art Unit: 1816

Serial No.: 08/737,904

Examiner: Schwadron, R.

Filed: November 20, 1996

Attorney Docket No.: IMI-040CP3

For: T Cell Epitopes of Ryegrass Pollen Allergen

Assistant Commissioner for Patents  
Washington, D.C. 20231

NOTIFICATION OF CHANGE OF MAILING ADDRESS

Sir:

The mailing address of Applicant's attorneys has changed. Please take notice that the correct correspondence address for this application should now be as follows:

**Customer No. 000959**, whose address is:

Lahive & Cockfield, LLP  
28 State Street  
Boston, MA 02109


Please enter this change of mailing address in the file of this matter and continue to direct all correspondence to the principal attorney of record, Amy E. Mandragouras, at this changed mailing address.

Certificate of First Class Mailing (37 CFR 1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date set forth below.


January 6, 1998

Date of Signature and of Mail Deposit

  
Amy E. Mandragouras, Reg. No. 36,207

Respectfully submitted,

LAHIVE & COCKFIELD, LLP

  
Amy E. Mandragouras  
Reg. No. 36,207  
Attorney for Applicant  
28 State Street  
Boston, MA 02109

Telephone: (617) 227-7400  
Telecopier: (617) 742-4214